Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Delix Therapeutics

Recent news which mentions Delix Therapeutics

Psilocybin Drug By Psilera Could Treat Frontotemporal Dementia Without Psychoactive Effects
Tickers NEWS
Tags News Health Care Psilera
From Benzinga
Delix's Non-Hallucinogen Completes Safe Administration To First Clinical Trial Cohort
Tags Market News Cannabis Markets
From Benzinga
Delix's Non-Hallucinogenic Psychoplastogen Enters Phase 1 Trial
Tags Psychoplastogens Next/Generation Psychedelics Cannabis
From Benzinga
Delix: Elucidating How Psychedelics Actually Induce Neuroplasticity Vs. SSRIs
Tags Psychoplastogens Psychedelics Delix Therapeutics
From Benzinga
Delix Inks Deal With Cellectricon; Psyched Wellness Partners With Spacestation
Tickers PSYCF
Tags Contracts Top Stories Benzinga
From Benzinga
Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma
Tickers DMTTF NUMIF TRYPF
Tags TRYPF Markets Cannabis
From Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
Tickers ATAI AWKNF CYBN FTRP
Tags News Penny Stocks ATAI
From Benzinga
Delix Therapeutics Raises $30M In Convertible Note Financing, Will Enhance Drug Development Program
Tags Benzinga Delix Therapeutics General
From Benzinga
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
Tickers ATAI NVMDF
Tags addiction Government Biotech
From Benzinga
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
Tickers BRAXF FTRP MCURF NVMDF
Tags Benzinga Delix Therapeutics FTRP
From Benzinga
'Psychedelics Without Hallucinations': Concept Get Closer To Human Trials With $70M Funding
Tags David Olson Benzinga Delix Therapeutics
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.